The one-time AAV9 gene therapy received full FDA approval for pediatric patients with preserved neurodevelopmental function, establishing the first approved treatment designed to alter the underlying course of MPS IIIA.
Key Takeaways
- The FDA approved Fayuvi for the neurological manifestations of mucopolysaccharidosis type IIIA in pediatric patients with preserved neurodevelopmental function.
- Ultragenyx reported a 23.5-point model-based cognitive treatment effect versus an external natural-history cohort.
- The approval validates systemic AAV9 delivery in a neurodegenerative lysosomal storage disorder, although early treatment, safety monitoring and long-term durability remain critical.
Data Snapshot
| Category | Details |
|---|---|
| Product | Fayuvi |
| Generic name | Rebisufligene etisparvovec-hopf |
| Developer | Ultragenyx Pharmaceutical |
| Indication | Neurological manifestations of MPS IIIA in pediatric patients with preserved neurodevelopmental function |
| Modality | Self-complementary AAV9 gene therapy |
| Administration | One-time intravenous infusion |
| Efficacy comparison | 17 treated patients vs. 27 external natural-history controls |
| Cognitive result | Company-reported model-based treatment effect of +23.5 Bayley-III raw-score points |
| Analysis period | 24–60 months of age |
| Statistical result | p<0.0001 |
| Regulatory status | Standard FDA approval |
| U.S. availability | Expected through qualified treatment centers within 30–60 days |
What Happened
The U.S. Food and Drug Administration approved Ultragenyx Pharmaceutical’s Fayuvi on September 17, 2026. It is the first FDA-approved treatment for mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome type A.
The approved indication is narrower than a general pediatric MPS IIIA label. Fayuvi is indicated for the treatment of neurological manifestations in pediatric patients who retain preserved neurodevelopmental function.
Fayuvi is administered as a single intravenous infusion. Its AAV9 vector delivers a functional copy of the SGSH gene, enabling cells to produce sulfamidase and reduce the lysosomal accumulation of heparan sulfate that drives the disease. (FDA approval announcement)
The approval followed an earlier FDA rejection related to manufacturing issues at Ultragenyx and a third-party facility. The agency accepted the company’s resubmission in April 2026 and placed it under priority review. (Fierce Pharma approval coverage)
Why It Matters
MPS IIIA is a progressive lysosomal storage disorder caused by insufficient sulfamidase activity. Children may develop normally during their earliest years before losing cognitive, language and motor abilities as heparan sulfate accumulates and neurological injury advances.
Fayuvi’s approval was supported by the pivotal Transpher A study and long-term follow-up data. The modified intention-to-treat analysis compared 17 treated patients with 27 untreated patients from an external natural-history cohort.
Ultragenyx reported a model-based treatment effect of +23.5 points in the Bayley-III cognitive raw score between 24 and 60 months of age. The difference was statistically significant at p<0.0001. Reductions in cerebrospinal-fluid heparan sulfate provided biochemical evidence of restored enzyme activity, while clinical follow-up now extends to nearly eight years in some patients.
Ultragenyx expects Fayuvi to become available for shipment to qualified U.S. treatment centers within 30–60 days. The approval makes Fayuvi the company’s second approved gene therapy and its sixth FDA-approved product overall. (Ultragenyx approval release)
How Fayuvi Targets the Underlying Disease
Fayuvi does not edit the patient’s endogenous SGSH variants. It supplies an additional functional SGSH expression cassette, allowing transduced cells to produce sulfamidase.
Some of the newly produced enzyme can be released and taken up by neighboring cells before being routed to their lysosomes. This process, known as lysosomal cross-correction, expands enzyme delivery beyond the cells directly transduced by AAV9.

The figure above summarizes how Fayuvi addresses the underlying biology of MPS IIIA. Rather than correcting the patient’s endogenous SGSH variants directly, Fayuvi delivers a functional SGSH expression cassette so transduced cells can produce sulfamidase. The restored enzyme activity supports lysosomal degradation of accumulated heparan sulfate, while lysosomal cross-correction may extend enzyme delivery beyond the cells directly transduced by the therapy. Mechanistically, the goal is to restore SGSH activity and reduce lysosomal heparan sulfate accumulation, with preservation of neurocognitive function as the intended downstream clinical benefit.
Safety and Treatment Burden
Fayuvi requires specialized administration and prolonged monitoring. Corticosteroid treatment begins one day before infusion and continues for at least eight weeks.
The prescribing information includes warnings for hepatotoxicity, thrombocytopenia, infusion and hypersensitivity reactions, thrombotic microangiopathy and a potential malignancy risk related to AAV-vector integration. No thrombotic microangiopathy cases were reported in the Fayuvi clinical studies, but post-treatment monitoring is recommended.
Fayuvi is therefore a one-time therapy, but not a simple one-time procedure. Treatment centers must coordinate eligibility assessment, immunosuppression, infusion management and long-term surveillance.
BP View
Fayuvi’s approval moves MPS IIIA treatment beyond symptom management. The therapy addresses the initiating biochemical defect and has shown both substrate reduction and a measurable difference in cognitive trajectory.
The evidence nevertheless comes from a small, single-arm program compared with an external natural-history cohort. A 23.5-point model-based treatment effect is meaningful in a disease defined by developmental plateau and regression, but it does not carry the same evidentiary strength as a randomized concurrent comparison.
The phrase “preserved neurodevelopmental function” is central to the approved indication. Fayuvi may limit continued substrate accumulation, but it should not be assumed to reverse extensive neuronal loss. Early diagnosis and referral will therefore influence how much function can realistically be preserved.
Commercial execution is the next test. Ultragenyx must identify eligible children, establish treatment-center capacity, secure reimbursement and maintain reliable vector manufacturing. Long-term follow-up will determine whether the cognitive separation from natural history remains durable as treated children grow older.

Related Post
Read my previous analysis of Skyhawk’s SKY-0515 Posts a 1.59-Point cUHDRS Advantage at 15 Months.
About Biopharma Perspective
Biopharma Perspective provides independent analysis of biotechnology, pharmaceutical development and regulatory events, with a focus on the scientific and strategic factors that shape clinical and commercial value.


Leave a Reply